CONMED Corporation Announces Third Quarter 2002 Results - Third Quarter Sales Up 7.6% to $113.3 Million - - Income Before Extraordinary Item Increases 64% to a Record $9.2 Million - - Powered Surgical Instrument Sales Grew 14.2% to $30.5 Million -

UTICA, N.Y., Oct. 17 /PRNewswire-FirstCall/ -- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the quarter ended September 30, 2002. Sales for the third quarter increased 7.6% to $113.3 million from $105.3 million in the comparable quarter last year. Income grew 64% to a record $9.2 million excluding an extraordinary item related to the Company's refinancing of its senior debt (additional detail provided below). This compares to income of $5.6 million in last year's third quarter excluding an unusual charge in that period relating to an acquisition (additional detail provided below). Earnings per diluted share, excluding the aforementioned extraordinary item, grew 45% to $0.32 on approximately four million additional shares outstanding compared to $0.22 excluding the unusual charge in the 2001 third quarter. On January 1, 2002, the Company adopted the provisions of FAS 142 relative to the cessation of goodwill amortization. This change caused net income to increase $1.4 million for the quarter and earnings per share to increase $0.05. Arthroscopy sales increased 4.0% to $38.6 million from $37.1 million in the same period last year. Powered Surgical Instrument sales grew 14.2% to $30.5 million compared to $26.7 million in the third quarter of 2001. As previously announced, the Company introduced its PowerPro(R) Battery Powered Instrument line in February 2002, with first shipments to customers in March 2002. During the third quarter 2002, sales of the PowerPro(R) battery systems amounted to approximately $5 million, in line with the Company's expectations. A portion of the quarter's sales of Powered Instruments were made to DePuy Orthopaedics, a Johnson and Johnson Company, for the purpose of providing sample units of the PowerPro(R) product to the DePuy sales force. These sample sales were at gross margins lower than the margins realized for units sold to end-user customers. Endoscopy revenues increased 15.2% to $9.1 million compared to $7.9 million in the same period last year. The endoscopy product line acquired from Imagyn in July 2001 has now completed a full year with CONMED. Thus, the sales growth is entirely organic. Sales of Patient Care Products grew 7.7% to $18.1 million compared to $16.8 million in the third quarter 2001. Electrosurgery revenues were $17.0 million, up slightly from the $16.8 million recorded in third quarter 2001. Mr. Joseph J. Corasanti, President and Chief Operating Officer, commented, "We are pleased to have reported strong third quarter results, with growth from all our product groups. Our percentage growth leader this quarter was Endoscopy, which grew at a rate of 15% reflecting our continued penetration into this market. Additionally, we are extremely pleased with the robust performance of Powered Surgical Instruments, which, on the strength of our PowerPro(R) Battery line, garnered sales of $30.5 million, up 14.2% over last year and in line with our expectations. Patient Care enjoyed rather healthy growth at a rate of 7.7%, underscoring our confidence that this product group will be a positive contributor to the overall financial strength of CONMED." In the three months ended September 30, 2002, the Company reduced its balance sheet debt by $4 million, and increased the usage of the receivable facility by $2 million causing a net reduction in financings of $2 million. For the nine months of 2002, the Company has reduced its debt and receivable financings a total of $20 million from operations. EBITDA amounted to $25.4 million for the quarter and $103.9 million for the trailing twelve months. As mentioned above, during August 2002, the Company entered into a new senior credit agreement, the proceeds of which were used to repay the previous senior credit agreement. The new agreement consists of a $100 million revolving line of credit, $1 million of which was used at September 30, 2002, and a $100 million fully utilized term loan. Unamortized deferred financing fees associated with the previous credit agreement amounting to $944,000, net of tax, have been written off as an extraordinary item due to the early extinguishment of debt. As previously disclosed, in July 2001, the Company completed the acquisition of certain surgical products from Imagyn Medical Technologies and incurred various transitional costs associated with integrating the acquisition into CONMED. During the quarter ended September 30, 2001, these costs amounted to $886,000, which reduced diluted earnings per share to $0.20. For the nine months ended September 30, 2002, CONMED reported revenues of $337.8 million, a 7.1% increase from $315.4 million in the first nine months of 2001. Net income before extraordinary item was $27.2 million, up 57% from $17.3 million last year prior to the Imagyn integration costs. Earnings per diluted share before extraordinary item grew 38% to $0.99 compared to $0.72 last year before the effects of the Imagyn integration costs. The change for FAS 142 with respect to goodwill accounting caused net income for the nine months ended September 2002 to increase by $4.2 million and diluted earnings per share to increase by $0.15. Mr. Corasanti continued, "We continue to expect the success of our business model and the historically strong fourth quarter to result in revenues of $120 - $125 million and diluted earnings per share of $0.36 - $0.40 for the quarter, and revenues of $458 - $463 million and diluted earnings per share before extraordinary item of $1.35 - $1.39 for the full year 2002. Looking ahead to the full year of 2003, we expect the continued execution of our strategy to generate top line organic growth of approximately 6%, similar to this year's organic growth rate. With that level of revenue growth, and through economies of scale and reduced interest costs from lower debt levels, we expect earnings per diluted share to increase approximately 15% over full year 2002 earnings per diluted share before the extraordinary item." CONMED is a medical technology company specializing in instruments, implants, and video equipment for arthroscopic sports medicine, and powered surgical instruments, such as drills and saws, for orthopedic, ENT, neuro-surgery, and other surgical specialties. The Company is also a leading developer, manufacturer and supplier of RF electrosurgery systems used routinely to cut and cauterize tissue in nearly all types of all surgical procedures worldwide, and endoscopy products such as trocars, clip appliers, scissors, and surgical staplers. The Company also manufactures and sells a full line of ECG electrodes for heart monitoring and other patient care products. Headquartered in Utica, New York, the Company's 2,500 employees distribute its products worldwide from eight manufacturing locations. This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company's performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, including the above mentioned anticipated revenues and earnings, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management's expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2001 and the Prospectus dated May 22, 2002; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; and/or (vii) the Company's ability to devise and execute strategies to respond to market conditions. CONMED CORPORATION CONSOLIDATED STATEMENTS OF INCOME (in thousands except per share amounts) (unaudited) For three months ended For nine months ended Sept. Sept. Sept. Sept. 2001 2002 2001 2002 Net sales $105,318 $113,332 $315,398 $337,806 Cost of sales 51,332 54,429 150,971 160,244 Selling and administrative 35,029 34,562 103,780 104,171 Research and development 3,491 4,253 10,663 12,155 89,852 93,244 265,414 276,570 Income from operations 15,466 20,088 49,984 61,236 Interest expense, net 7,630 5,765 23,809 18,748 Income before income taxes and extraordinary item 7,836 14,323 26,175 42,488 Provision for income taxes 2,821 5,156 9,423 15,295 Income before extraordinary item 5,015 9,167 16,752 27,193 Extraordinary item, net of income taxes -- 944 -- 944 Net income $5,015 $8,223 $16,752 $26,249 Per share data: Income before extraordinary item Basic $.20 $.32 $.71 $1.01 Diluted .20 .32 .70 .99 Extraordinary item Basic -- .03 -- .03 Diluted -- .04 -- .03 Net Income Basic .20 $.29 $.71 $.98 Diluted .20 .28 .70 .96 Weighted average common shares Basic 24,806 28,613 23,657 26,870 Diluted 25,381 29,043 23,990 27,470 CONMED CORPORATION CONSOLIDATED CONDENSED BALANCE SHEETS (in thousands) ASSETS (unaudited) December Sept. 2001 2002 Current assets: Cash and cash equivalents $1,402 $2,513 Accounts receivable, net 51,188 55,770 Inventories 107,390 117,880 Other current assets 4,569 4,468 Total current assets 164,549 180,631 Property, plant and equipment, net 91,026 94,856 Goodwill and other assets, net 446,033 445,280 Total assets $701,608 $720,767 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Current portion of long-term debt $73,429 $2,272 Accrued interest 4,954 1,158 Other current liabilities 41,454 44,352 Total current liabilities 119,837 47,782 Long-term debt 262,500 251,560 Other long-term liabilities 35,637 41,753 Total liabilities 417,974 341,095 Shareholders' equity: Capital accounts 160,591 228,383 Retained earnings 128,240 154,489 Accumulated other comprehensive loss (5,197) (3,200) Total shareholders' equity 283,634 379,672 Total liabilities and shareholders' equity $701,608 $720,767 OTHER FINANCIAL INFORMATION (unaudited, in thousands) Three months ended Nine months ended Sept. Sept. 2001 2002 2001 2002 EBITDA $23,159 $25,448 $72,012 $76,809 Depreciation 2,303 2,327 6,648 6,731 Amortization 4,504 3,033 14,494 8,842 Capital expenditures 4,049 2,133 12,704 10,561